These guidelines have been prepared by the Sub directorate: Maternal Health for the guidance of health workers (doctors and midwives) providing obstetric, surgical and anaesthetic services for pregnant women in district clinics, health centres and district hospitals. These guidelines are intended fo...r use in clinics, community health centres and district hospitals where specialist services are not normally available. The guidelines deal mainly with the diagnosis and especially the management of common and serious pregnancy problems. The assumption is made that the reader has a basic knowledge and understanding about the care of pregnant women. With a few exceptions (e.g. pre-eclampsia), there is no mention of aetiology and pathogenesis of the conditions described.https://www.knowledgehub.org.za/elibrary/guidelines-maternity-care-south-africa-2016
more
Mid-term review of The National AIDS Programme 2011-15
October 2013
Ce manuel est destiné aux prestataires de soins chargés de la prise en charge des cas de paludisme simple et grave au niveau des structures de santé. C’est un document de référence facile d’utilisation, fournissant des connaissances et des compétences utiles aux agents de santé prenant e...n charge les cas de paludisme.
more
Le Plan Stratégique National de Lutte contre le Paludisme 2021–2027 du Burundi expose la vision d’un Burundi sans décès lié au paludisme d’ici 2027. Le programme vise à réduire de 60 % la morbidité et à atteindre zéro mortalité grâce à une couverture universelle en prévention (m...oustiquaires imprégnées, pulvérisation intradomiciliaire, traitement préventif intermittent), une prise en charge efficace à tous les niveaux (structures sanitaires et communautaires), un renforcement des capacités institutionnelles, et une surveillance épidémiologique renforcée. Le plan insiste sur la bonne gouvernance, l’équité, la mobilisation des ressources, la communication et l’innovation, tout en s’alignant sur les objectifs nationaux et internationaux de santé publique.
more
This guidance covers different options for banning or phasing out a pesticide and suggests related risk reduction measures to be taken during the phase-out period. A key focus of this guidance is how to take action to manage, prevent, minimize, and communicate about identified risks during the imple...mentation of a phase-out strategy. It contains a description of legal aspects to consider when phasing out a product and illustrates how a risk communication plan can be structured and implemented. How different stakeholders may be involved when a pesticide is going to be phased out is also described.
more
Scope: The purpose of this guideline is to assist health care providers caring for patients with suspected or confirmed arboviral disease caused by dengue, chikungunya, Zika or yellow fever viruses. This guideline includes recommendations on the management of patients admitted to health care facilit...ies (defined for the purpose of this guidance as “severe disease”) and those seen in outpatient facilities (defined for the purpose of this guidance as “non-severe disease”).
Target audience: This guideline is designed primarily for health care providers who manage patients with clinically apparent arboviral infections. The guideline can be applied at all levels of the health system, including community-based care, primary care, emergency departments and hospital wards.
more
Access to safe, effective and quality-assured health products and technologies is crucial for achieving universal health coverage and primary health care goals. The continued growth of the aging population; increasing burden of noncommunicable diseases; growing burden of mental health issues; climat...e change; shifting patterns of vector borne diseases, fungal disease and waterborne diseases; antimicrobial resistance; and new infectious hazards create an ongoing need for equitable access to safe, effective and quality-assured health products and technologies, and renewed investments in research and development for innovative health products and technologies.
The coronavirus pandemic exposed the inequalities in access to health products, highlighting the need for longer-term strategies to strengthen access to health products and technologies outside of and in emergency situations. While technological and scientific advances present an opportunity to increase access to health products and technologies, the risk of increasing inequality due to higher prices for new health products and technologies; the persisting problem of substandard and falsified medical products; a lack of skilled workforce in many low- and middle-income countries; and a lack of data for decisionmaking and for measuring progress present significant challenges.
more
Mapping Report - Catalonia (Spain).
Advance Copy
Accessed: 08.03.2020